Cargando…
Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-bindin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663300/ https://www.ncbi.nlm.nih.gov/pubmed/38023247 http://dx.doi.org/10.3389/fonc.2023.1252700 |
_version_ | 1785138368997228544 |
---|---|
author | Mairinger, Elena Wessolly, Michael Buderath, Paul Borchert, Sabrina Henrich, Larissa Mach, Pawel Steinborn, Julia Kimming, Rainer Jasani, Bharat Schmid, Kurt Werner Bankfalvi, Agnes Mairinger, Fabian Dominik |
author_facet | Mairinger, Elena Wessolly, Michael Buderath, Paul Borchert, Sabrina Henrich, Larissa Mach, Pawel Steinborn, Julia Kimming, Rainer Jasani, Bharat Schmid, Kurt Werner Bankfalvi, Agnes Mairinger, Fabian Dominik |
author_sort | Mairinger, Elena |
collection | PubMed |
description | BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-binding proteins comprising various isoforms. MTs play a role in tumor development and drug resistance. Moreover, MTs influence inflammatory processes by regulating zinc homeostasis. In particular, T-cell function and polarization are particularly susceptible to changes in zinc status. The aim of the present study was to investigate a possible role of MT-mediated immune response and its association with prognostic outcome in ovarian cancer. METHODS: A retrospective study was conducted on a clinically well-characterized cohort of 24 patients with HGSOC treated at the University Hospital of Essen. Gene expression patterns for anti-cancer immunogenicity-related targets were performed using the NanoString nCounter platform for digital gene expression analysis with the appurtenant PanCancer Immune Profiling panel, consisting of 770 targets and 30 reference genes. Tumor-associated immunohistochemical MT protein expression was evaluated using a semi-quantitative four-tier Immunohistochemistry (IHC) scoring. RESULTS: MT immunoexpression was detected in 43% (10/23) of all HGSOC samples. MT immunoexpression levels showed a significant association to survival, leading to prolonged progression-free and overall survival in positively stained tumors. Furthermore, T-cell receptor signaling gene signature showed a strong activation in MT-positive tumors. Activated downstream signaling cascades resulting in elevated interferon-gamma expression with a shift in the balance between T helper cells (T(H)1 and T(H)2) could be observed in the MT-positive subgroup. In addition, a higher expression pattern of perforin and several granzymes could be detected, overall suggestive of acute, targeted anti-cancer immune response in MT-positive samples. CONCLUSION: This is the first study combining broad, digital mRNA screening of anti-tumor immune response–associated genes and their relation to MT-I/II in ovarian cancer. MT overexpression is associated with molecular characteristics of an anti-cancer immune response and is a strong prognostic marker in ovarian HGSOC. The observed immune cell activation associated with tumor MT expression comprises but is not limited to T cells and natural killer cells. |
format | Online Article Text |
id | pubmed-10663300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106633002023-01-01 Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma Mairinger, Elena Wessolly, Michael Buderath, Paul Borchert, Sabrina Henrich, Larissa Mach, Pawel Steinborn, Julia Kimming, Rainer Jasani, Bharat Schmid, Kurt Werner Bankfalvi, Agnes Mairinger, Fabian Dominik Front Oncol Oncology BACKGROUND: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One of those are metallothioneins (MTs), metal-binding proteins comprising various isoforms. MTs play a role in tumor development and drug resistance. Moreover, MTs influence inflammatory processes by regulating zinc homeostasis. In particular, T-cell function and polarization are particularly susceptible to changes in zinc status. The aim of the present study was to investigate a possible role of MT-mediated immune response and its association with prognostic outcome in ovarian cancer. METHODS: A retrospective study was conducted on a clinically well-characterized cohort of 24 patients with HGSOC treated at the University Hospital of Essen. Gene expression patterns for anti-cancer immunogenicity-related targets were performed using the NanoString nCounter platform for digital gene expression analysis with the appurtenant PanCancer Immune Profiling panel, consisting of 770 targets and 30 reference genes. Tumor-associated immunohistochemical MT protein expression was evaluated using a semi-quantitative four-tier Immunohistochemistry (IHC) scoring. RESULTS: MT immunoexpression was detected in 43% (10/23) of all HGSOC samples. MT immunoexpression levels showed a significant association to survival, leading to prolonged progression-free and overall survival in positively stained tumors. Furthermore, T-cell receptor signaling gene signature showed a strong activation in MT-positive tumors. Activated downstream signaling cascades resulting in elevated interferon-gamma expression with a shift in the balance between T helper cells (T(H)1 and T(H)2) could be observed in the MT-positive subgroup. In addition, a higher expression pattern of perforin and several granzymes could be detected, overall suggestive of acute, targeted anti-cancer immune response in MT-positive samples. CONCLUSION: This is the first study combining broad, digital mRNA screening of anti-tumor immune response–associated genes and their relation to MT-I/II in ovarian cancer. MT overexpression is associated with molecular characteristics of an anti-cancer immune response and is a strong prognostic marker in ovarian HGSOC. The observed immune cell activation associated with tumor MT expression comprises but is not limited to T cells and natural killer cells. Frontiers Media S.A. 2023-11-08 /pmc/articles/PMC10663300/ /pubmed/38023247 http://dx.doi.org/10.3389/fonc.2023.1252700 Text en Copyright © 2023 Mairinger, Wessolly, Buderath, Borchert, Henrich, Mach, Steinborn, Kimming, Jasani, Schmid, Bankfalvi and Mairinger https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Mairinger, Elena Wessolly, Michael Buderath, Paul Borchert, Sabrina Henrich, Larissa Mach, Pawel Steinborn, Julia Kimming, Rainer Jasani, Bharat Schmid, Kurt Werner Bankfalvi, Agnes Mairinger, Fabian Dominik Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title_full | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title_fullStr | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title_full_unstemmed | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title_short | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
title_sort | tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663300/ https://www.ncbi.nlm.nih.gov/pubmed/38023247 http://dx.doi.org/10.3389/fonc.2023.1252700 |
work_keys_str_mv | AT mairingerelena tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT wessollymichael tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT buderathpaul tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT borchertsabrina tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT henrichlarissa tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT machpawel tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT steinbornjulia tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT kimmingrainer tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT jasanibharat tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT schmidkurtwerner tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT bankfalviagnes tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma AT mairingerfabiandominik tumorcellcytoplasmicmetallothioneinexpressionassociateswithdifferentialtumorimmunogenicityandprognosticoutcomeinhighgradeserousovariancarcinoma |